⌘K
t
Scancell Holdings plc announced on 20 October 2023 an update regarding its final results for the year ended 30 April 2023. The Company's auditor, BDO LLP, requested additional time to complete the standard audit due to unforeseen circumstances, stating the audit is substantially complete with no material issues advised. Scancell is targeting the publication of its audited financial results once the auditor finalises processes.
| Date | 20 Oct 2023 |
| Time | 07:00:07 |
| Category | Miscellaneous |
| ID | 7379Q |
20 October 2023
Scancell Holdings plc
("Scancell" or the "Company")
Update on Final Results
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides the following update in relation to the publication of its results for the year ended 30 April 2023.
The Company's auditor, BDO LLP, has requested additional time to complete their standard audit due to unforeseen circumstances impacting the audit engagement team. Scancell's Board has been advised that the audit is substantially complete and has not been advised of any material audit issues.
Accordingly, the Company is targeting the publication of its audited financial results as soon as the auditor completes their final processes.
-ENDS-
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7710 7600 |
|
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) |
|
|
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) |
+44 (0) 20 7886 2500 |
|
Freddy Crossley/Emma Earl (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
ICR Consilium |
+44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Matthew Neal/Chris Welsh |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/